{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:48:33Z","timestamp":1765079313679},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,11]],"date-time":"2016-09-11T00:00:00Z","timestamp":1473552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Taiwan","doi-asserted-by":"publisher","award":["CMRPG8C0961"],"award-info":[{"award-number":["CMRPG8C0961"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jfma.2016.08.006","type":"journal-article","created":{"date-parts":[[2016,10,9]],"date-time":"2016-10-09T15:56:20Z","timestamp":1476028580000},"page":"512-521","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs"],"prefix":"10.1016","volume":"116","author":[{"given":"Ming-Chao","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-Mo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2016.08.006_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol Int"},{"issue":"Suppl. 1","key":"10.1016\/j.jfma.2016.08.006_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2005-915644","article-title":"Epidemiology and natural history of hepatitis B","volume":"25","author":"McMahon","year":"2005","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jfma.2016.08.006_bib3","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.08.006_bib4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.08.006_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"5 Suppl.","key":"10.1016\/j.jfma.2016.08.006_bib6","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/hep.22884","article-title":"Hepatitis B virus DNA levels and outcomes in chronic hepatitis B","volume":"49","author":"Chen","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.08.006_bib7","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.08.006_bib8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.25937","article-title":"Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy","volume":"57","author":"Lai","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.08.006_bib9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/jvh.12054","article-title":"Long-term outcome of hepatitis B virus-related chronic hepatitis under protracted nucleos(t)ide analogues","volume":"20","author":"Niro","year":"2013","journal-title":"J Viral Hepatol"},{"key":"10.1016\/j.jfma.2016.08.006_bib10","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"Sung","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2016.08.006_bib11","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/gutjnl-2013-306409","article-title":"Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease","volume":"63","author":"Cho","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2016.08.006_bib12","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2016.08.006_bib13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2016.08.006_bib14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.08.006_bib15","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1128\/AAC.49.7.2720-2728.2005","article-title":"Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection","volume":"49","author":"Menne","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2016.08.006_bib16","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/hep.1840360707","article-title":"Fibrosis and disease progression in hepatitis C","volume":"36","author":"Marcellin","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.08.006_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s005350300025","article-title":"Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis","volume":"38","author":"Hung","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2016.08.006_bib18","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"},{"year":"2003","series-title":"ATC index with DDDs 2003","author":"WHO Collaborating Center for Drugs Statistics Methodology","key":"10.1016\/j.jfma.2016.08.006_bib19"},{"key":"10.1016\/j.jfma.2016.08.006_bib20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.10122","article-title":"Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan","volume":"98","author":"Chen","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jfma.2016.08.006_bib21","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.08.006_bib22","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.08.006_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.antiviral.2011.10.018","article-title":"Precore\/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy","volume":"93","author":"Hung","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jfma.2016.08.006_bib24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2014.08.045","article-title":"Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2016.08.006_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2012.10.025","article-title":"Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis","volume":"58","author":"Kumada","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2016.08.006_bib26","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/jac\/dku041","article-title":"Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B","volume":"69","author":"Hsu","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jfma.2016.08.006_bib27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1440-1746.2011.06695.x","article-title":"Natural history of chronic hepatitis B revealed","volume":"26","author":"Chen","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2016.08.006_bib28","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/cncr.22242","article-title":"Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma","volume":"107","author":"Lu","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2016.08.006_bib29","first-page":"557","article-title":"Development of hepatocellular carcinoma after successful management of esophageal variceal bleeding","volume":"67","author":"Chen","year":"2004","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jfma.2016.08.006_bib30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jhep.2009.01.014","article-title":"Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis","volume":"50","author":"Ripoll","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2016.08.006_bib31","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2009.27.3003","article-title":"Statin use and risk of prostate cancer recurrence in men treated with radiation therapy","volume":"28","author":"Gutt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2016.08.006_bib32","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/1055-9965.EPI-13-0414","article-title":"Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age","volume":"22","author":"McDougall","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jfma.2016.08.006_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/cen.12570","article-title":"Statin use and thyroid cancer: a population-based case-control study","volume":"83","author":"Hung","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jfma.2016.08.006_bib34","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/pros.21401","article-title":"Statins increase the risk of prostate cancer: a population-based case-control study","volume":"71","author":"Chang","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.jfma.2016.08.006_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10552-013-0326-6","article-title":"Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies","volume":"25","author":"Liu","year":"2014","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jfma.2016.08.006_bib36","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00228-013-1547-z","article-title":"Statins are associated with reduced risk of gastric cancer: a meta-analysis","volume":"69","author":"Wu","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jfma.2016.08.006_bib37","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2016.08.006_bib38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.2011.36.0917","article-title":"Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection","volume":"30","author":"Tsan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2016.08.006_bib39","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/jac\/dkt147","article-title":"Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants","volume":"68","author":"Yang","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jfma.2016.08.006_bib40","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jgh.12499","article-title":"Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment","volume":"29","author":"Fung","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2016.08.006_bib41","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.09.031","article-title":"Telbivudine improves renal function in patients with chronic hepatitis B","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2016.08.006_bib42","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/jac\/dkr495","article-title":"A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice","volume":"67","author":"Tsai","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jfma.2016.08.006_bib43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jgh.12436","article-title":"Comparing the efficacy and clinical outcome of telbivudine and entecavir naive patients with hepatitis B virus-related compensated cirrhosis","volume":"29","author":"Tsai","year":"2014","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966461630198X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966461630198X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T20:24:41Z","timestamp":1536351881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092966461630198X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S092966461630198X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2016.08.006","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2016.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}